PYC Therapeutics Limited
Research PYC Therapeutics Limited (PYC.AX) on Bullrun: market cap AUD 1.88B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPYC.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 1.88B
- Financial periodFY2026
- Net income-AUD 43.34M
- Free cash flow-AUD 45.05M
Valuation Snapshot
latest market cap is AUD 1.88B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 43.34M | -AUD 45.05M | n/a | n/a | AUD 53.56M | AUD 624.99K | AUD 693.33M |
| FY2025 | n/a | -AUD 50.30M | -AUD 52.54M | n/a | -0.1 | AUD 153.05M | AUD 1.02M | AUD 169.57M |
| FY2024 | n/a | -AUD 37.73M | -AUD 38.90M | n/a | -0.09 | AUD 66.87M | AUD 1.11M | AUD 80.50M |
| FY2023 | n/a | -AUD 22.79M | -AUD 24.91M | n/a | -0.07 | AUD 15.57M | AUD 315.49K | AUD 27.75M |
| FY2022 | n/a | n/a | n/a | n/a | -0.04 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 1.88B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About PYC Therapeutics Limited
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PYC Therapeutics Limited's market cap?
PYC Therapeutics Limited's market capitalization is AUD 1.88B.
What does PYC Therapeutics Limited do?
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11.